Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 402


Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.

Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.


Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).

Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O.

J Thorac Oncol. 2010 Sep;5(9):1354-60. doi: 10.1097/JTO.0b013e3181e77a78.


Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.

Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR.

J Thorac Oncol. 2011 Jul;6(7):1179-89. doi: 10.1097/JTO.0b013e31821b4ce0.


Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas.

Jung JH, Jung CK, Choi HJ, Jun KH, Yoo J, Kang SJ, Lee KY.

Pathol Res Pract. 2009;205(6):409-16. doi: 10.1016/j.prp.2008.12.015. Epub 2009 Feb 20.


c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.

Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, Tamura T, Asamura H, Furuta K, Tsuda H.

J Thorac Oncol. 2012 Feb;7(2):331-9. doi: 10.1097/JTO.0b013e318241655f.


P63 expression in lung carcinoma: a tissue microarray study of 408 cases.

Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7.


p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.

Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M, Scagliotti GV.

J Thorac Oncol. 2011 Mar;6(3):473-81. doi: 10.1097/JTO.0b013e31820b86b0.


PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.

PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.


Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.

Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM.

J Thorac Oncol. 2010 Apr;5(4):442-7. doi: 10.1097/JTO.0b013e3181d40fac.


Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.

Huang Q, Fan J, Qian X, Lv Z, Zhang X, Han J, Wu F, Chen C, Du J, Guo M, Hu G, Jin Y.

J Cancer Res Clin Oncol. 2016 Jan;142(1):263-72. doi: 10.1007/s00432-015-2040-0. Epub 2015 Aug 30.


Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.

Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT.

J Thorac Oncol. 2010 Oct;5(10):1536-43. doi: 10.1097/JTO.0b013e3181ea510a.


Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.

Jacobsen B, Muley T, Meister M, Dienemann H, Christensen IJ, Santoni-Rugiu E, Lærum OD, Ploug M.

J Thorac Oncol. 2013 Feb;8(2):152-60. doi: 10.1097/JTO.0b013e318279d503.


Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.

Zhang Y, Yang H, Qiu Y, Deng Q, Liu J, Zhao M, He P, Mo M, Zou X, He J.

Med Oncol. 2014 Mar;31(3):803. doi: 10.1007/s12032-013-0803-5. Epub 2014 Jan 23.


Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.

Tsoukalas N, Aravantinou-Fatorou E, Tolia M, Giaginis C, Galanopoulos M, Kiakou M, Kostakis ID, Dana E, Vamvakaris I, Korogiannos A, Tsiambas E, Salemis N, Kyrgias G, Karameris A, Theocharis S.

Anticancer Res. 2017 Apr;37(4):1773-1778.


S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.

Smith SL, Gugger M, Hoban P, Ratschiller D, Watson SG, Field JK, Betticher DC, Heighway J.

Br J Cancer. 2004 Oct 18;91(8):1515-24.


Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).

Wang JL, Wu DW, Cheng ZZ, Han WZ, Xu SW, Sun NN.

Asian Pac J Cancer Prev. 2014;15(12):4865-9.


Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.


Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH.

J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.


Differential expression of inflammasomes in lung cancer cell lines and tissues.

Kong H, Wang Y, Zeng X, Wang Z, Wang H, Xie W.

Tumour Biol. 2015 Sep;36(10):7501-13. doi: 10.1007/s13277-015-3473-4. Epub 2015 Apr 25.


Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.

Deng B, Sun Z, Jason W, Yang P.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S701-8. doi: 10.1245/s10434-013-3184-2. Epub 2013 Aug 1.

Supplemental Content

Support Center